ALLIANCE A011801

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

New, Open

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Eligible for screening study DCP 001

NCT#04457596